Zostavax Shingles Vaccine Lawsuit Set for Trial in January 2022

The U.S. District Judge presiding over all federal Zostavax lawsuits has scheduled the first bellwether trial to begin in January 2022, which will help the parties gauge how juries may respond in nearly 2,000 similar claims filed over side effects of the shingles vaccine.

Zostavax was introduced in 2006 as the first shingles vaccine on the market in the United States, involving a single-dose injection that contained a live virus. However, plaintiffs allege the live virus was not sufficiently weakened, resulting in severe complications and injury among some users receiving the shingles vaccine.

Given similar questions of fact and law raised in complaints filed throughout the federal court system, all claims are currently centralized before U.S. District Judge Harry Bartle in the U.S. District Court for the Eastern District of Pennsylvania, as part of a federal multidistrict litigation (MDL).

Learn More About

Zostavax Lawsuits

Side effects of the shingles vaccine Zostavax may result in the development of a painful and persistent strain of shingles

Learn More About this Lawsuit SEE IF YOU QUALIFY FOR COMPENSATION

As part of the coordinated proceedings, Judge Bartle has established a “bellwether” program, where a small group of representative claims are being prepared for early trial dates in the MDL, which are designed to help evaluate the strengths and weakness of each side’s position, and promote eventual settlement negotiations.

In a pretrial order (PDF) issued on June 30, Judge Bartle scheduled the first bellwether trial to begin on January 18, 2022. The specific case which will go before a jury on that date will be chosen from what is known as the “Group A Bellwether Pool”, which consists of six lawsuits selected by the parties.

The first Zostavax shingles vaccine trial was previously expected to begin in November 2021, but that schedule was vacated by this new pretrial order. The parties are expected to complete all depositions of expert witnesses in the Group A cases by September 3, and any motions to exclude specific testimony must be filed by September 17. A deadline of December 30, 2021 has been established for plaintiffs to file any motions in limine, with a January 7, 2022, deadline for defendants.

Each of the nearly 2,000 product liability lawsuits filed against Merck & Co. raise similar allegations, alleging that the drug maker withheld critical information about side effects of the Zostavax shingles vaccine, and failed to disclose evidence that users were experiencing severe and persistent outbreaks and other auto-immune problems after receiving the vaccine, such as meningitis, acute disseminated encephalopmyelitis (ADEM), paralysis and other health problems.

While the outcome of the bellwether trials will not be binding on other plaintiffs, it will be closely watched by parties involved in the litigation and are expected to greatly influence any eventual shingles vaccine settlements that the manufacturer may offer to individuals who experienced problems with Zostavax, which may be necessary to avoid the eventual need for hundreds of individual trial dates to be scheduled in U.S. District Courts nationwide in the coming years.

2 Comments

  • KathyJanuary 5, 2023 at 12:51 am

    I had a shingle shot in 2018, and have had terrible dizziness and fatigue for 5 years now. Have been to 8 doctors and no answers to what is going on. Have connected the dots 5 years later, and am still sick.

  • LindaApril 16, 2022 at 12:07 pm

    Aug1,2016 had zoster shingle shot at pharmacy in Seattle , 10 days later developed peripheral neuropathy in my feet to this day. I do not have PN from diabetes. Constant burning pain , after 6 years of medical treatments no relief, concluded to be chemical poisoning from shingles zoster shot by doctors.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted yesterday)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 3 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.